Overcoming the Species Barrier in cGAS-STING Drug Discovery: Why Humanized Mice are Essential for Translation

Mediating Cytosolic DNA Sensing via the cGAS-STING Axis

STING is an endoplasmic reticulum-resident adaptor protein that plays a core role in innate immune recognition of cytosolic DNA ^[2]. Under physiological conditions, free DNA is rarely present in the cytoplasm. When pathogen infection or cellular damage, including tumor cell death, results in cytosolic DNA accumulation, cyclic GMP-AMP synthase (cGAS) is activated and catalyzes the production of cyclic GMP-AMP (cGAMP) ^[3]. cGAMP then binds STING1 and triggers its activation, conformational change, and intracellular trafficking, leading to recruitment and activation of TANK-binding kinase 1 (TBK1). Activated TBK1 phosphorylates transcription factors such as interferon regulatory factor 3 (IRF3) and NF-κB, thereby inducing type I interferons (IFN-I) and multiple pro-inflammatory cytokines that drive host defense against intracellular danger signals ^[3-4].

Dysregulation of this pathway is inextricably linked to a broad spectrum of human pathologies:

Autoimmune Diseases: Constitutive overactivation of STING, often due to gain-of-function mutations, leads to severe autoinflammatory conditions like STING-associated vasculopathy with onset in infancy (SAVI) ^[3-4]. Preclinical studies show that knocking out Sting1 in mouse models significantly alleviates systemic lupus erythematosus (SLE)-like inflammation and atherosclerosis, highlighting its therapeutic potential in inflammation ^[5].

Alzheimer’s Disease (AD): Aberrant activation of the STING pathway is closely tied to neuroinflammation, amyloid-β (Aβ) deposition, and tau pathology in AD. Cytosolic DNA, such as leaked mitochondrial DNA in AD brains, activates cGAS, which via the STING-TBK1-IRF3 axis prompts microglia to release inflammatory cytokines like TNF-α and IL-1β, exacerbating protein aggregation and neuronal damage ^{[3, 6-7]}. Inhibiting STING has been shown to alleviate microglial activation, reduce Aβ plaques, and improve cognitive function ^[7-8]. Targeting STING via siRNA can promote microglial polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, offering a potential therapeutic avenue for AD ^[7-8].

Immuno-Oncology: Conversely, STING acts as a crucial "switch" in the tumor microenvironment to turn immunologically "cold" tumors "hot" by regulating anti-tumor immunity and inflammatory responses. Activating this pathway promotes tumor antigen cross-presentation and effector T cell infiltration, enhancing tumor immunogenicity and boosting responsiveness to immune checkpoint inhibitors (ICI), making the cGAS-STING pathway a promising target for cancer vaccines and immunotherapy ^[9].

Addressing Species Specificity as a Bottleneck in STING Translation

Despite the therapeutic promise, STING-targeted drug discovery faces a severe hurdle: significant species differences between human and mouse STING proteins ^[10]. Evolutionary and structural divergences in human vs. mouse STING lead to disparate binding affinities or activation effects for the same ligand across species.

A critical example recently published in Nature Chemical Biology underscores this issue: the potent STING inhibitor H-151, which exhibits excellent efficacy in mice, is completely inactive in human primary peripheral blood mononuclear cells (PBMCs) ^[11-12].

H-151 acts by covalently binding to the C91 residue of mouse STING to block its palmitoylation ^[11]. However, in human STING (hSTING), palmitoylation at C91 is not essential for activation. Instead, hSTING is more dependent on basal palmitoylation at C64 and disulfide bond formation at C148 to drive oligomerization ^[11]. Because of these divergent activation mechanisms, molecules designed to target the murine C91 site fail to suppress human STING signaling ^[11].

This limitation of traditional wild-type mice in predicting clinical efficacy in humans has compelled researchers to shift focus toward developing molecules that target human-specific STING mechanisms. Furthermore, some agonists targeting the STING transmembrane domain (TMD) are only effective against human STING, making wild-type mice unsuitable for in vivo efficacy evaluations of these candidates ^[13-14].

The Solution: huSTING1 Humanized Mice as a Vital Translational Tool

Establishing humanized mouse models expressing human STING1 is essential to break the drug discovery bottleneck. For instance, using a STING1 humanized mouse model, researchers validated the novel agonist INI3069, which selectively activates human STING. The model demonstrated that INI3069 significantly inhibits the growth of MC38 colon cancer and B16 melanoma tumors, a therapeutic effect found to be highly dependent on CD8+ T cells ^[13]. This clearly illustrates the irreplaceable role of humanized models in evaluating the efficacy of human-selective STING regulators.

Empowering Drug Discovery with Cyagen’s Validated huSTING1 Humanized Mice

To accelerate translational research on STING1-targeted therapeutics, Cyagen has independently developed the huSTING1 humanized mouse model (Product ID: C001712). Using advanced gene editing technology, the entire murine Sting1 gene locus was replaced with the corresponding human genomic sequence, ensuring precise and stable expression of human STING1 within the mouse.

Here is a summary of the key validation data:

1. Confirming Functional Gene Expression of Human STING1

Testing confirms that huSTING1 mice exhibit significant human STING1 mRNA expression in the spleen, lung, liver, and brain, while murine Sting1 expression is absent. The expression levels and tissue distribution align with expected physiological patterns.

2. Detecting Expression of Human STING1 Protein

Protein-level analysis further confirms the specific expression of human STING1 protein in multiple tissues of huSTING1 mice.

Conclusion